4024-05-9 Usage
Uses
Used in Pharmaceutical Research:
(R)-2-hydroxypropaniMidaMide hydrochloride is used as a chiral building block for the synthesis of pharmaceuticals and biologically active molecules, leveraging its unique molecular structure and chirality to create new drugs with improved efficacy and selectivity.
Used in Organic Synthesis:
(R)-2-hydroxypropaniMidaMide hydrochloride is used as a catalyst in organic synthesis, enhancing the efficiency and selectivity of chemical reactions, which is crucial for the production of complex organic compounds and pharmaceutical intermediates.
Used in Asymmetric Catalysis:
(R)-2-hydroxypropaniMidaMide hydrochloride is used in the preparation of chiral ligands for asymmetric catalysis, a technique that allows for the selective formation of one enantiomer over another in chemical reactions, which is essential for creating enantiomerically pure compounds with specific biological activities.
Used in the Development of New Chemical Processes:
(R)-2-hydroxypropaniMidaMide hydrochloride contributes to the advancement of new chemical processes by providing a versatile and enantioselective building block, facilitating the creation of innovative synthetic pathways and methodologies in the chemical and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 4024-05-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,0,2 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 4024-05:
(6*4)+(5*0)+(4*2)+(3*4)+(2*0)+(1*5)=49
49 % 10 = 9
So 4024-05-9 is a valid CAS Registry Number.
4024-05-9Relevant academic research and scientific papers
Sorbitol dehydrogenase inhibitors
-
, (2008/06/13)
This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.
